Maruti Suzuki is aggressively working on an all-new car, as Maruti’s engineers embark on an independent full-model change capability, something not attempted before. The company’s idea is to develop a car that would co-exist with the Alto, the country’s largest-selling car with monthly volumes averaging over 30,000 units. The car will be meant primarily for the Indian market and the idea behind the model was to constantly introduce new models while also developing the company’s R&D capability to develop, design and engineer a model on its own.
Utility vehicle maker Mahindra & Mahindra (M&M) was in the process of finalising product platforms jointly with South Korea’s SsangYong Motor Co which it acquired last year. M&M is investing in product and brand development in SsangYong Motor Co. Both the teams of M&M and SsangYong Motor Co are working together to develop new product platforms over the next 3-4 years. M&M had acquired a 70 per cent stake for $378 million in the South Korea’s third-largest maker of sport utility vehicles, Ssangyong Motor Co in 2010.
Ranbaxy Laboratories has closed a unit in the US as part of a rationalisation process. The plant was under scrutiny by US authorities for violation of regulatory norms. The liquid-manufacturing plant in Gloversville, NY, had been shut as it was operating at sub-optimal level. The plant closure is not expected to impact the company’s revenues. In December 2009, the US Food and Drug Administration (FDA) had issued a warning to the plant for violation of manufacturing norms and halted approval of new drugs.